What's in the News

FDA accepted a supplemental new drug application to extend ZORYVE cream 0.3 percent plaque psoriasis treatment to children aged 2 to 5, with a PDUFA target action date of June 29, 2026 (Company press release).

FDA approved ZORYVE cream 0.05 percent for once daily, steroid-free treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age in the United States (Company press release).

Arcutis commercially launched ZORYVE cream 0.05 percent for children 2 to 5 with atopic dermatitis, supported by patient access programs such as ZORYVE Direct and Arcutis Cares (Company press release).

New long-term data showed ZORYVE foam 0.3 percent is safe, well tolerated, and efficacious for up to 52 weeks in seborrheic dermatitis, with high rates of clear or almost clear skin (American Journal of Clinical Dermatology publication, company summary).

Company issued 2026 guidance, projecting between 455 million dollars and 470 million dollars in net product revenue, underscoring expectations for continued portfolio growth (Company guidance).

Valuation Changes

The fair value estimate has risen slightly, from 31 dollars to approximately 31 dollars and 63 cents per share.

The discount rate has increased marginally, from about 7.04 percent to roughly 7.05 percent, reflecting a very small adjustment to perceived risk.

The revenue growth assumption has risen slightly, from around 31.56 percent to approximately 31.84 percent, indicating modestly higher growth expectations.

The net profit margin has increased modestly, from roughly 35.91 percent to about 36.29 percent, implying a small improvement in long term profitability.

The future P/E multiple has edged up slightly, from about 19.60 times to roughly 19.66 times forward earnings, signaling a minor upward shift in valuation multiples.

Key Takeaways

Expansion of ZORYVE indications and partnerships targets underserved populations, supporting sustained revenue and margin improvement through diversification and operating leverage.
Demand for innovative non-steroidal treatments and ongoing R&D investments enhance long-term growth, portfolio expansion, and market share amid favorable demographic trends.
Heavy dependence on a single product, elevated spending, evolving payer risks, limited pipeline, and rising competition threaten revenue, profitability, and long-term growth prospects.

Catalysts

About Arcutis Biotherapeutics

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.What are the underlying business or industry changes driving this perspective?

Arcutis is poised to sustain and accelerate top-line revenue growth through continued expansion of ZORYVE indications, targeting large, underserved populations such as pediatric atopic dermatitis and scalp psoriasis, while leveraging broadening insurance coverage and the ongoing shift away from steroid use in chronic dermatologic conditions.
The aging population and rising prevalence of chronic skin diseases, coupled with increased societal focus on wellness and early intervention, are driving long-term demand and patient growth for innovative non-steroidal treatments-well-aligned with ZORYVE's differentiated safety profile, underpinning sustained revenue expansion.
Progressive conversion of topical steroid prescriptions (currently 69% of the addressable market) to ZORYVE and efficient penetration into new channels (e.g., primary care and pediatrics via partnerships) set up a durable, multi-year growth runway and diversification, supporting both top-line growth and improving net margins due to operating leverage.
Ongoing investments in R&D for adjacent indications and pipeline innovation, supported by increasing cash flow from core products and disciplined capital allocation, enable future portfolio expansion without significant incremental cash burn, improving long-term earnings visibility.
Strong IP protection and a scalable commercial infrastructure, alongside opportunities for strategic partnerships or future lifecycle management (e.g., adding new formulations), position Arcutis to capture a larger share of a growing market, supporting upward re-rating of earnings and valuation multiples over time.

Arcutis Biotherapeutics Earnings and Revenue Growth

Arcutis Biotherapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Arcutis Biotherapeutics's revenue will grow by 37.0% annually over the next 3 years.
Analysts assume that profit margins will increase from -35.4% today to 35.0% in 3 years time.
Analysts expect earnings to reach $237.0 million (and earnings per share of $1.79) by about September 2028, up from $-93.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $302.8 million in earnings, and the most bearish expecting $80.6 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 14.4x on those 2028 earnings, up from -20.5x today. This future PE is lower than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 2.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Arcutis Biotherapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The company's heavy reliance on the ZORYVE franchise for the bulk of its current and expected future revenue creates significant business concentration risk; any commercial underperformance, slower-than-expected uptake, or future competition in the non-steroidal topical space could materially impact top-line growth and overall earnings.
Evolving insurance and payer dynamics, including the slow and uncertain expansion of Medicare Part D coverage due to ongoing disruptions from the Inflation Reduction Act, present a long-term risk to patient access and reimbursement rates, potentially leading to revenue shortfalls or impaired net margins.
Despite recent improvement in operating leverage, persistent high R&D and SG&A spending (including a need for disciplined capital allocation and continued investment in launches and commercialization) risks future operating losses and could force dilution via equity raises or increase reliance on debt, negatively impacting net margins and long-term earnings per share.
Tougher generic and biosimilar competition as patent protections expire-or as broader "topical" baskets encourage switching based on pricing-could compress margins and erode market share, especially if ZORYVE is unable to secure a unique class designation for reimbursement, impacting future revenue and profitability.
The limited internal pipeline highlighted by the discontinuation of ARQ-255, and uncertainty around the potential success and scalability of new indications or external business development deals, exposes the company to R&D risk and may limit long-term growth potential, dampening revenue expansion and future earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $21.857 for Arcutis Biotherapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $19.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $676.8 million, earnings will come to $237.0 million, and it would be trading on a PE ratio of 14.4x, assuming you use a discount rate of 6.8%.
Given the current share price of $15.94, the analyst price target of $21.86 is 27.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises

ARQT: Pediatric Approvals And Long-Term Data Will Support Gradual Portfolio Expansion